ATE374200T1 - 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen - Google Patents
7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungenInfo
- Publication number
- ATE374200T1 ATE374200T1 AT03709984T AT03709984T ATE374200T1 AT E374200 T1 ATE374200 T1 AT E374200T1 AT 03709984 T AT03709984 T AT 03709984T AT 03709984 T AT03709984 T AT 03709984T AT E374200 T1 ATE374200 T1 AT E374200T1
- Authority
- AT
- Austria
- Prior art keywords
- jun
- treatment
- azaindole
- neurodegenerative disorders
- inhibitors
- Prior art date
Links
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0207491A GB0207491D0 (en) | 2002-03-28 | 2002-03-28 | Inhibitors |
| GB0217330A GB0217330D0 (en) | 2002-07-25 | 2002-07-25 | Inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374200T1 true ATE374200T1 (de) | 2007-10-15 |
Family
ID=28676498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03709984T ATE374200T1 (de) | 2002-03-28 | 2003-03-17 | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7534800B2 (de) |
| EP (1) | EP1490364B1 (de) |
| JP (1) | JP2005534618A (de) |
| KR (1) | KR20040111445A (de) |
| CN (1) | CN100368411C (de) |
| AT (1) | ATE374200T1 (de) |
| AU (1) | AU2003214412A1 (de) |
| CA (1) | CA2480317A1 (de) |
| DE (1) | DE60316542T2 (de) |
| IL (1) | IL164187A0 (de) |
| WO (1) | WO2003082868A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10037759A1 (de) * | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌 |
| GB0305142D0 (en) * | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| US7432375B2 (en) | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
| US7612086B2 (en) * | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
| JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ret調節剤の開発のための化合物および方法 |
| GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| GB0405055D0 (en) * | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| ATE383361T1 (de) * | 2004-06-21 | 2008-01-15 | Hoffmann La Roche | Pyrrazolopyrimidinderivate |
| SE0401655D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| US7452993B2 (en) * | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| RU2389728C2 (ru) * | 2004-07-27 | 2010-05-20 | Сгкс Фармасьютиклз, Инк. | Модуляторы киназы на основе производных пирролопиридина |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| NZ553267A (en) * | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| CN101027302B (zh) * | 2004-07-27 | 2011-05-11 | Sgx药物公司 | 吡咯并吡啶激酶调节剂 |
| WO2006049890A1 (en) | 2004-10-27 | 2006-05-11 | Janssen Pharmaceutica N.V. | Pyridine imidazoles and aza-indoles as progesterone receptor modulators |
| FR2884821B1 (fr) * | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| FR2887881B1 (fr) * | 2005-07-01 | 2009-10-09 | Pierre Fabre Medicament Sa | Inhibiteurs de proteines kinases |
| GB0516156D0 (en) * | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| WO2007067537A1 (en) * | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| ATE522536T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| CN101952295B (zh) | 2008-02-25 | 2013-11-20 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| ATE517107T1 (de) | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitoren |
| ATE519763T1 (de) | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
| RU2503676C2 (ru) | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| JP5370957B2 (ja) * | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| EP2356116A1 (de) | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituierte pyrrolo[2,3-b]pyridine und pyrazine |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| MX2012013194A (es) | 2010-05-20 | 2013-01-22 | Hoffmann La Roche | Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak). |
| PE20141360A1 (es) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN103613591B (zh) * | 2012-09-29 | 2016-04-13 | 上海科州药物研发有限公司 | 作为cMet抑制剂的化合物及其制备方法和用途 |
| EP2738172A1 (de) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | Neue bizyklische Verbindungen als CRAC-Kanalmodulatoren |
| US9206188B2 (en) * | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| EP3180329B1 (de) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles als nr2b rezeptor inhibitoren |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| PL3558321T3 (pl) | 2016-12-23 | 2023-10-23 | Felicitex Therapeutics, Inc. | Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b |
| EP3596075B1 (de) | 2017-03-15 | 2023-10-11 | F. Hoffmann-La Roche AG | Azaindole als inhibitoren von hpk1 |
| EP3774732A4 (de) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Substituiertes pyridin und pyrimidine und ihre verwendung als glun2b-rezeptormodulatoren |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用 |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| EP3983413A1 (de) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituierte pyrazolo-pyrazine und deren verwendung als glun2b-rezeptor-modulatoren |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| JP7677983B2 (ja) * | 2020-01-23 | 2025-05-15 | マイオフォルテ セラピューティクス,インク. | Pgdh阻害剤、およびその作製と使用の方法 |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| KR102347368B1 (ko) * | 2020-11-03 | 2022-01-07 | (주)케이메디켐 | 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4719218A (en) | 1985-12-12 | 1988-01-12 | Smithkline Beckman Corporation | Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor |
| HU207074B (en) | 1990-12-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing optically active cis and trans 14-(n-substituted-aminomethyl)-eburnane derivatives and pharmaceutical compositions comprising same |
| GB9026926D0 (en) | 1990-12-12 | 1991-01-30 | Smith Kline French Lab | Novel process |
| SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
| JP3119758B2 (ja) | 1993-02-24 | 2000-12-25 | 日清製粉株式会社 | 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬 |
| FR2732969B1 (fr) | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| HRP20000209A2 (en) * | 1997-10-20 | 2001-04-30 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| AU3210799A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU747776B2 (en) | 1998-10-30 | 2002-05-23 | Merck & Co., Inc. | Thrombin inhibitors |
| WO2000026210A1 (en) | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Thrombin inhibitors |
| KR20010101266A (ko) | 1998-12-17 | 2001-11-14 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌 |
| ES2301255T3 (es) | 1998-12-17 | 2008-06-16 | F. Hoffmann-La Roche Ag | 4,5-pirazinaxindoles como inhibidores de proteinoquinasas. |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6239132B1 (en) | 1999-04-23 | 2001-05-29 | Merck & Co., Inc. | Thrombin inhibitors |
| DE60041763D1 (de) | 1999-04-23 | 2009-04-23 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
| KR20080028516A (ko) | 1999-08-19 | 2008-03-31 | 시그널 파머슈티컬스 인크 | Jnk억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물 |
| DE60006634T2 (de) | 1999-12-07 | 2004-04-15 | Fuji Photo Film Co., Ltd., Minami-Ashigara | Fluoreszente materialen |
| HUP0203895A3 (en) * | 1999-12-24 | 2004-09-28 | Aventis Pharma Ltd West Mallin | Substituted azaindoles and pharmaceutical compositions containing them and their use |
| DE60132975T2 (de) | 2000-01-06 | 2009-02-26 | Merck Frosst Canada Inc., Kirkland | Neue substanzen und verbindungen als protease-inhibitoren |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| EP1490365B1 (de) | 2002-03-28 | 2010-02-10 | Eisai R&D Management Co., Ltd. | Azaindole als hemmstoffe von c-jun n-terminalen kinasen |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌 |
| US20030235042A1 (en) * | 2002-06-24 | 2003-12-25 | Harris Jeffrey M. | Carrier card and method |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| US7432375B2 (en) | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
| GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| US7612086B2 (en) | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
| GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
-
2003
- 2003-03-17 KR KR10-2004-7015415A patent/KR20040111445A/ko not_active Ceased
- 2003-03-17 AT AT03709984T patent/ATE374200T1/de not_active IP Right Cessation
- 2003-03-17 CA CA002480317A patent/CA2480317A1/en not_active Abandoned
- 2003-03-17 IL IL16418703A patent/IL164187A0/xx unknown
- 2003-03-17 JP JP2003580333A patent/JP2005534618A/ja active Pending
- 2003-03-17 DE DE60316542T patent/DE60316542T2/de not_active Expired - Fee Related
- 2003-03-17 CN CNB038121034A patent/CN100368411C/zh not_active Expired - Fee Related
- 2003-03-17 AU AU2003214412A patent/AU2003214412A1/en not_active Abandoned
- 2003-03-17 EP EP03709984A patent/EP1490364B1/de not_active Expired - Lifetime
- 2003-03-17 WO PCT/GB2003/001112 patent/WO2003082868A1/en not_active Ceased
- 2003-03-17 US US10/509,128 patent/US7534800B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003214412A1 (en) | 2003-10-13 |
| JP2005534618A (ja) | 2005-11-17 |
| CN100368411C (zh) | 2008-02-13 |
| DE60316542T2 (de) | 2008-07-03 |
| KR20040111445A (ko) | 2004-12-31 |
| EP1490364B1 (de) | 2007-09-26 |
| US7534800B2 (en) | 2009-05-19 |
| CA2480317A1 (en) | 2003-10-09 |
| DE60316542D1 (de) | 2007-11-08 |
| IL164187A0 (en) | 2005-12-18 |
| WO2003082868A1 (en) | 2003-10-09 |
| US20050272761A1 (en) | 2005-12-08 |
| CN1656094A (zh) | 2005-08-17 |
| EP1490364A1 (de) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60316542D1 (de) | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen | |
| DE60331219D1 (de) | Azaindole als hemmstoffe von c-jun n-terminalen kinasen | |
| ATE297394T1 (de) | Jun kinase inhibitoren | |
| WO2004078756A3 (en) | Jnk inhibitors | |
| GB0516156D0 (en) | JNK inhibitors | |
| WO2004101565A3 (en) | Jnk inhibitors | |
| ATE468337T1 (de) | 3,5-disubstituierte 1h-pyrrolo ä2,3-bü pyridine als jnk-inhibitoren | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| PT1660507E (pt) | Inibidores de proteassoma e seus métodos de utilização | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| EP1608627A4 (de) | Bicyclische anilidspirohydantoine als cgrp-rezeptorantagonisten | |
| MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
| DE602007012363D1 (de) | 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| ATE451369T1 (de) | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes | |
| NO20064852L (no) | Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser | |
| PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
| MXPA05009535A (es) | Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos. | |
| WO2004030620A3 (en) | Novel tyrosine kinase inhibitors | |
| MXPA05008438A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. | |
| IL151695A0 (en) | Substituted beta-carbolines with ikb-kinase inhibiting activity | |
| TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
| TW200724140A (en) | Hydantoin compounds | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |